Chronic Rhinosinusitis Balloon Begins Trial
A US study is evaluating a drug-coated balloon designed to improve outcomes for chronic rhinosinusitis patients undergoing sinus surgery.
Tag: chronic rhinosinusitis with nasal polyps
All
Latest
Chronic Rhinosinusitis Balloon Begins Trial
A US study is evaluating a drug-coated balloon designed to improve outcomes for chronic rhinosinusitis patients undergoing sinus surgery.
Read More
Bronchiectasis + Chronic Rhinosinusitis Patients More Likely to Have P. aeruginosa in Mucus
Researchers found that patients with both bronchiectasis and chronic rhinosinusitis are more likely to test positive for Pseudomonas aeruginosa (P aeruginosa).
Read More
Airborne Toxins Trigger Unique Chronic Rhinosinusitis in Veterans
Veterans with chronic rhinosinusitis (CRS) who were exposed to burn pits and other toxins show a marked increase in sinus mast cells.
Read More
CRSwNP Patients Showed Sleep Improvements After Surgery
Sleep quality for patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) improved after endoscopic surgery, showing longer REM sleep durations, according to a study published in Sleep Science.
Read More
Airiver Medical Secures IDE Approval for Study of Chronic Rhinosinusitis Treatment
Airiver received investigational device exemption approval from the US FDA to begin a pivotal clinical trial of the Airiver ESSpand Sinus Drug Coated Balloon in patients with chronic rhinosinusitis.
Read More
Deployed Military Veterans Had 55% Higher Asthma Risk
American military veterans deployed to Iraq or Afghanistan had a higher risk of asthma, chronic rhinitis, chronic rhinosinusitis, and nasal polyposis compared with non-deployed peers.
Read More
Tezspire Approved in EU for CRSwNP
The European Commission approved Tezspire (tezepelumab) as an add-on therapy with intranasal corticosteroids for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
FDA Approves Tezspire for CRSwNP
Tezspire (tezepelumab-ekko) is now FDA-approved for chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 and older.
Read More
EU Panel Recommends Tezspire for Chronic Rhinosinusitis with Nasal Polyps
AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Read More
Prioritizing Prevention of Chronic Respiratory Diseases
ERS leaders are calling for health systems to prioritize and integrate the care of chronic respiratory diseases (CRDs) across Europe.
Read More
ISS Astronauts Suffer Nasal, Sinus Problems
Sinus and congestion problems are more than just earthly annoyances, according to new research on astronauts from the International Space Station.
Read More
FDA Approves Biosimilar Omlyclo for Asthma
Omlyclo (omalizumab-igec) is the first and only biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe persistent asthma, CRSwNP, IgE-mediated food allergy, and chronic spontaneous urticaria.
Read More
Mepolizumab Reduced Need for Repeat Sinus Surgeries in CRwNP Patients
Patients using mepolizumab (Nucala) experienced significant improvement in nasal polyps, nasal obstruction, smell and overall symptoms.
Read More
Tezspire Significantly Reduced Nasal Congestion, Polyp Size in CRwNP Patients
Tezspire, an add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma, showed significant benefits for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in a Phase 3 clinical trial.
Read More